INS and Hyperglycemia: MET is an oral antidiabetic drug (OAD) that reduces hyperglycemia in patients with T2DM by inhibiting hepatic glucose production (i.e., by improving hepatic insulin sensitivity) and by slowing glucose absorption from the gut [2, 61].